• BDW. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89–95.

• Richards AM. New biomarkers in heart failure: applications in diagnosis, prognosis and guidance of therapy. Rev Esp Cardiol 2010; 63 (6): 635-9.

• Obesity, metabolic syndrome and diabetes: cardiovascular implications and therapy. Alegría Ezquerra E et al. , Rev Esp Cardiol. 2008 Jul;61(7):752-64.

• Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. Ridker PM et al. N Engl J Med. 2002 Nov 14;347(20):1557-65.

• C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Ridker PM, et al. Circulation. 2003 Jan 28;107(3):391-7

• Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Ridker PM et al. Am J Cardiol. 2010 Jul 15;106(2):204-9.

• Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. Ridker PM, et al. Clin Chem. 2012 May;58(5):877-86.

• Lipidología: Presente y futuro. Dr. Jorge Vilariño y Dr. Alberto Lorenzati. Ediciones Médicas del Sur, 2013. ISBN: 9789872608361

• Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Pearson T et al. Circulation 2003;107:499-511.

• Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Persson M et al.
Arterioscler Thromb Vasc Biol 2007; 27(6):1411-6.

• Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Davidson et al. Am J Card Suppl 2008;101:51F–57F

• Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome. Miksztowicz V et al. Metabolism 2008;57:1493

• Increased MMP-2 in healthy postmenopausal women. Muzzio ML et al. Ann Clin Biochem. 2012 Jan;49(Pt 1):75-9.

• Use of metabolic markers to identify overweight individuals who are insulin resistant. McLaughlin T, et al. Ann Intern Med. 2003 Nov 18;139(10):802-9.

• Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? McLaughlin T, et al. Am J Cardiol. 2005 Aug 1; 96:99-404.